MEI Pharma Inc. (MEIP)
2.76
0.07 (2.60%)
At close: Jan 15, 2025, 1:15 PM
undefined% (undefined)
| Bid | 2.74 |
| Market Cap | 18.39M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -6.99 |
| PE Ratio (ttm) | -0.39 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2.76 |
| Volume | 11,785 |
| Avg. Volume (20D) | 51,885 |
| Open | 2.75 |
| Previous Close | 2.69 |
| Day's Range | 2.65 - 2.76 |
| 52-Week Range | 2.30 - 5.45 |
| Beta | undefined |
About MEIP
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cycl...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2003
Employees 28
Stock Exchange NASDAQ
Ticker Symbol MEIP
Website https://www.meipharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MEIP stock is "Hold." The 12-month stock price forecast is $7, which is an increase of 153.62% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
5 months ago ·
Source
+21.33%
MEI Pharma shares are trading higher after the com...
Unlock content with
Pro Subscription
